Former type
|
Public |
---|---|
Traded as | TSX: CCT NASDAQ: CTRX |
Industry | PBM and Health informatics |
Fate | Acquired |
Predecessor | SXC Health Solutions |
Successor | UnitedHealth Group |
Founded | 1993 |
Defunct | 2015 (2015) |
Headquarters | Schaumburg, Illinois, United States |
Key people
|
Terrece C Burke, Chair Mark A. Thierer (CEO) |
Revenue | $14,780.094 mil49% 2013 |
Net income
|
$287.739 mil138% 2013 |
Total assets | $7,995.763 mil8% 2013 |
Total equity | $4,908.490 mil6% 2013 |
Number of employees
|
4,000 (Dec 31, 2013) 1,433 (Dec.31,2011) 1,216 (Feb.25,2011) |
Divisions | informedRx Healthcare IT Group HBS Health Business Systems |
Website | www |
Catamaran Corporation (formerly SXC Health Solutions) is a Schaumburg, Illinois based pharmacy benefit management company that sells services related to pharmacy benefit management and medical record keeping to businesses in the United States. Working independently of the government and insurance companies allows it to operate as a third party verifier; the RxCLAIM online claim processing system allows for prescription drug claims to be processed online if the customer lives in and fills his/her prescription in the United States. SXC has three separate but interrelated business segments which deal with prescription drug programs. For 2013 23% of company revenue came from Cigna Corporation.
Most of the company's growth came in 2008 when it doubled in size; Between 2005 and 2010 revenue increased 3,400%. As a Canadian startup, the company received venture capital subsidies from the Canadian government in addition to private investments. These subsidies allowed the business to grow initially and establish its business model in advance of its initial public offering, which was offered through the NASDAQ exchange in 2009. The success of the mixed public and private approach in SXC's case has been called "perhaps the best example of the flexibility and the value added by the Canadian hybrid system." In 2013 company revenue increased by 49% thanks to a full year of prescription claims at the Catalyst division, and additional volumes from newly acquired Restat. On 30 March 2015, it was announced that Catamaran will be acquired by OptumRx (A UnitedHealth Group company).
Systems Xellence (SXC), founded in 1993, was a Canadian company that first went public in 1995 when it joined the TSX. Six years later, in 2001, it acquired ComCoTec, an Illinois-based software business. After going public on the NASDAQ stock market in 2006, the company shifted its headquarters from Milton, Ontario to Chicago, the city ComCoTec was based in. SXC was one of the first companies to build technology used in pharmacy benefit management.
In February 2008, eight months after the company changed its name to SXC Health Solutions, it acquired National Medical Health Card Systems, Inc. (NMHC) for US$143 million in a move that doubled its size and workforce. It is now known as InformedRx, a division of SXC. On December 19, 2008, the company also acquired Zynchros, an eight-year-old Seattle-based formulary management business.
SXC purchased private company MedfusionRx, Inc on December 2, 2010 for $100 million. Reasons for the acquisition include an interest in strengthening SXC's position in the speciality pharmacy market and improving cost cutting capabilities in the management of complex conditions and improving supportive care. MedfusionRx provides voice messaging services to people in all 50 US states as well as other clinical services to over 9000 patients. The messages have to do with medical treatment assistance including the delivery and refill reminders of medication and patient monitoring for people with chronic diseases. It was founded in 2003 in Birmingham, Alabama. Medfusion manages $270 million in drug spending.
In 2012, SXC agreed to buy rival Catalyst Health Solutions Inc. in a roughly $4.14 billion cash-and-stock deal. Shortly thereafter, SXC Health Solutions Corp. renamed the company, Catamaran Corp.
In 2015, Health insurer UnitedHealth Group agreed to buy pharmacy benefit manager Catamaran Corp in a deal worth about $12.8 billion.
SXC has three main business segments: InformedRx, Healthcare IT Group (HCIT), and Health Business Systems.
InformedRx is SXC Health Solution's pharmacy benefit management service. It deals with formulary administration, benefit plan design and management, pharmacy network management, drug utilization review, clinical services and consulting, reporting and information analysis, mail services and specialty pharmacy, and consumer web services.
Healthcare IT Group focuses on the technological aspects of the company. It includes the RxCLAIM, RxTRACK, and RxPORTAL customer interfaces, which support the electronic processing of prescriptions. It also includes pharmacy technology services (technology relied upon by application service providers), as well as Zynchros, a provider of formulary management tools.
Health Business Systems are management systems providers to retail, institutional or nursing home, and mail order pharmacy environments.
SXC Health Solutions has been used by various organizations, including Cigna, HealthSpring, PharMerica, TennCare, the Boston Medical Center HealthNet Plan, and Health Alliance of Michigan.
2016-01-28 | Upgrade | JMP Securities | Underperform to Market Perform | |
2015-04-22 | Downgrade | Maxim Group | Buy to Hold | |
2015-04-08 | Downgrade | Argus | Buy to Hold | |
2015-04-07 | Downgrade | Raymond James | Outperform to Market Perform | |
2015-04-07 | Downgrade | Jefferies Group | Buy to Hold | $61.50 |
2015-04-07 | Downgrade | Raymond James Financial Inc. | Outperform to Market Perform | |
2015-04-06 | Downgrade | BMO Capital Markets | Outperform to Market Perform | |
2015-04-01 | Upgrade | Dougherty & Co | Sell | |
2015-04-01 | Downgrade | Mizuho | Buy to Neutral | $57.00 |
2015-04-01 | Downgrade | Leerink Swann | Outperform to Market Perform | $60.00 to $61.50 |
2015-03-31 | Downgrade | FBR & Co. | Outperform to Market Perform | $61.50 |
2015-03-31 | Boost Price Target | CIBC | Sector Outperformer | $77.75 |
2015-03-31 | Boost Price Target | Scotiabank | Sector Perform | $61.50 |
2015-03-31 | Boost Price Target | Barclays | Equal Weight | $58.00 to $61.00 |
2015-03-31 | Downgrade | RBC Capital | Sector Perform | $61.50 |
2015-03-31 | Downgrade | SunTrust | Buy to Neutral | |
2015-03-31 | Downgrade | Cowen and Company | Outperform to Market Perform | $57.00 to $61.50 |
2015-03-31 | Downgrade | William Blair | Outperform to Market Perform | |
2015-03-31 | Downgrade | FBR & Co | Outperform to Market Perform | $61.50 |
2015-03-31 | Boost Price Target | Barclays PLC | Equal Weight | $58.00 to $61.00 |
2015-03-31 | Downgrade | Royal Bank Of Canada | Sector Perform | $61.50 |
2015-03-31 | Downgrade | SunTrust Banks Inc. | Buy to Neutral | |
2015-03-30 | Reiterated Rating | FBR & Co. | Outperform to Market Perform | $61.50 |
2015-03-30 | Reiterated Rating | Credit Suisse | Outperform to Neutral | $61.00 to $61.50 |
2015-03-30 | Reiterated Rating | Credit Suisse Group AG | Outperform to Neutral | $61.00 to $61.50 |
2015-03-23 | Initiated Coverage | Mizuho | Buy | $57.00 |
2015-02-27 | Reiterated Rating | Deutsche Bank | Hold | $47.00 to $53.00 |
2015-02-27 | Boost Price Target | Leerink Swann | Outperform | $55.00 to $60.00 |
2015-02-27 | Boost Price Target | Barclays | Equal Weight | $51.00 to $58.00 |
2015-02-27 | Reiterated Rating | Deutsche Bank AG | Hold | $47.00 to $53.00 |
2015-01-21 | Initiated Coverage | Stephens | Overweight | |
2015-01-08 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $54.00 to $56.00 |
2015-01-06 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $50.00 |
2014-11-03 | Reiterated Rating | Credit Suisse | Outperform | $54.00 to $55.00 |
2014-10-31 | Reiterated Rating | Deutsche Bank | Hold | $46.00 to $47.00 |
2014-10-31 | Reiterated Rating | Citigroup Inc. | Neutral | $48.00 to $51.00 |
2014-10-31 | Boost Price Target | FBR & Co. | Outperform | $51.00 to $53.00 |
2014-10-09 | Reiterated Rating | Morgan Stanley | Equal Weight | |
2014-08-11 | Initiated Coverage | FBR & Co. | Outperform | $52.00 |
2014-08-04 | Reiterated Rating | Barclays | Equal Weight | $47.00 to $50.00 |
2014-08-04 | Reiterated Rating | Maxim Group | Buy | |
2014-08-04 | Boost Price Target | Cowen and Company | Outperform | $54.00 to $56.00 |
2014-05-02 | Reiterated Rating | Barclays | Equal Weight | $47.00 |
2014-05-01 | Reiterated Rating | Dougherty & Co | Buy | |
2014-04-22 | Lower Price Target | Cowen and Company | $57.00 to $51.00 | |
2014-04-21 | Upgrade | Ned Davis Research | Neutral to Buy | |
2014-04-15 | Upgrade | Oppenheimer | Market Perform to Outperform | $50.00 |
2014-04-14 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $55.00 to $48.00 |
2014-04-14 | Reiterated Rating | Jefferies Group | Sell | |
2014-03-31 | Lower Price Target | Jefferies Group | Buy | $70.00 to $58.00 |
2014-03-05 | Initiated Coverage | Barclays | Equal Weight | $45.00 |
2014-02-28 | Downgrade | ISI Group | Buy to Neutral | $50 |
2014-02-28 | Downgrade | CIBC | Outperform to Sector Perform | |
2014-02-28 | Downgrade | Evercore ISI | Buy to Neutral | $50.00 |
2014-02-27 | Boost Price Target | Cowen and Company | $59.00 to $61.00 | |
2014-02-18 | Initiated Coverage | Citigroup Inc. | Buy to Neutral | |
2014-01-22 | Initiated Coverage | Argus | Buy | $65.00 |
2013-12-17 | Downgrade | Goldman Sachs | Buy to Neutral | $61.00 to $50.00 |
2013-11-27 | Reiterated Rating | Dougherty & Co | Buy | $57.00 |
2013-11-20 | Initiated Coverage | Deutsche Bank | Hold | $51.00 |
2013-11-01 | Reiterated | Dougherty & Company | Buy | $75 to $57 |
2013-11-01 | Reiterated Rating | Goldman Sachs | Buy | $69.00 to $61.00 |
2013-11-01 | Lower Price Target | Dougherty & Co | Buy | $75.00 to $57.00 |
2013-10-14 | Reiterated Rating | Morgan Stanley | Hold | $60.00 |
2013-10-14 | Lower Price Target | Evercore ISI | Buy | $65.00 to $60.00 |
2013-10-10 | Initiated Coverage | RBC Capital | Outperform | |
2013-09-23 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $60.00 |
2013-07-15 | Upgrade | ISI Group | Buy to Strong Buy | $62 |
2013-06-11 | Reiterated | ISI Group | Buy | $59.50 to $68 |
2016-01-28 | Upgrade | JMP Securities | Underperform to Market Perform | |
2015-04-22 | Downgrade | Maxim Group | Buy to Hold | |
2015-04-08 | Downgrade | Argus | Buy to Hold | |
2015-04-07 | Downgrade | Raymond James | Outperform to Market Perform | |
2015-04-07 | Downgrade | Jefferies Group | Buy to Hold | $61.50 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CTRX 4 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Adamant Biomedical Investments AG | 0.21M |
Placemark Investments, Inc. | 65441 |
SpiderRock Trading LLC | 559 |
NEW ENGLAND SECURITIES CORP /MA/ | 280 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
Reddon Philip | 0.02% (36660) | CTRX / |
Thorne Curtis | 0.01% (13850) | CTRX / |